Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2012

View Archived Issues

Novel small molecules target RNA binding site of human DDX3X

Telaprevir improves hepatitis C therapy in HIV-1-coinfected patients

Anti-fibrillogenic agents designed via out-of-plane substitutions show therapeutic potential

Studies demonstrate various therapeutic applications for SEH inhibition

Horizon Discovery and RFUMS to develop human cellular CF model

Recruitment complete in phase II BVT-115959 trial

Mologen seeks approval for study of MGN-1703 in NSCLC

OncoSec begins enrollment at two new sites for metastatic melanoma trial

New P2X4 receptor antagonist is active in models of neuropathic pain

Marina Biotech and ProNAi Therapeutics enter license agreement for DNAi-based therapies

New dipeptide calpain inhibitors reported by Banyan Biomarkers

Enanta presents novel candidate hepatitis C drugs

Novel p53-based peptidomimetics developed at Aileron Therapeutics

Shionogi & Co. divulges novel potential obesity drugs

Novel anti-infectives announced by Novacta Biosystems

Almirall attains new marketing rights to Sativex

Abbott begins phase III studies in hidradenitis suppurativa

Biogen Idec and MAKScientific enter MS agreement

Shire announces planned acquisition

Grifols acquires majority share in Araclon Biotech

Treatment begins in phase III study of CSL Behring's fibrinogen concentrate

Clinuvel provides update on phase III Scenesse trial

Aeras receives grant to develop new vaccines against TB

Thrombogenics and Alcon enter commercialization agreement for ocriplasmin

Novartis withdraws applications for new rivastigmine indication

Repligen commences first-in-human trial of HD inhibitor in Friedreich's ataxia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.